The answer, according to the study, is a resounding yes. Among fifty treatment-naïve patients, forty-eight—96 percent—achieved a sustained virologic response at twelve weeks after the end of therapy, the standard benchmark for a cure. Among fifty patients previously treated with pegylated interferon plus ribavirin, the punishing regimen that dominated hepatitis C care for decades, forty-seven—94 percent—achieved the same outcome. The difference between the two groups was not statistically significant, with a p-value of 0.6, meaning that prior treatment history essentially did not matter for success with the newer regimen. In practical terms, nearly every patient in the cohort, regardless of their therapeutic past, left the study virologically cured.

To understand why this finding matters, it helps to appreciate how radically hepatitis C treatment has changed. Before the arrival of direct-acting antivirals in the mid-2010s, the standard of care combined weekly injections of pegylated interferon with oral ribavirin for up to forty-eight weeks. Interferon works indirectly, amplifying the immune system’s antiviral state, and it produces flu-like symptoms, depression, cytopenias, and a host of other toxicities. Cure rates hovered around 50 to 70 percent for the most common viral genotypes, and many patients either could not tolerate the regimen or relapsed after completing it. Direct-acting antivirals changed the equation by targeting viral proteins directly. Ledipasvir inhibits the hepatitis C virus NS5A protein, which is essential for viral replication and assembly, while sofosbuvir targets the NS5B RNA-dependent RNA polymerase, the enzyme the virus needs to copy its genome. Adding ribavirin, a nucleoside analog that enhances viral clearance through incompletely understood mechanisms, further guards against relapse in certain patient populations.

The Sana’a study enrolled one hundred adults with chronic hepatitis C between April 2019 and March 2021, dividing them evenly between the naïve and previously treated cohorts. All participants received ledipasvir/sofosbuvir plus ribavirin for twelve weeks. The researchers measured hepatitis C viral load using the COBAS TaqMan real-time polymerase chain reaction platform, a highly sensitive assay capable of detecting even trace amounts of viral RNA. Viral load was assessed at baseline and again twelve weeks after the completion of therapy to determine sustained virologic response, or SVR12. Alongside virologic endpoints, the team tracked a battery of clinical and laboratory parameters, including the liver enzymes alanine aminotransferase and aspartate aminotransferase, alpha-fetoprotein as a marker of hepatocellular carcinoma risk, and a full panel of hematological indices. Adverse events and medication adherence were recorded throughout.

The safety profile of the regimen proved reassuring. Anemia was the most frequent laboratory abnormality observed, and the researchers attributed it to ribavirin, which is well known to cause hemolytic anemia by depleting red blood cells of ATP and other nucleotides. Ribavirin-induced anemia is typically dose-dependent and reversible, and in this cohort it did not force anyone off treatment. Other adverse events were mild to moderate in severity and included fatigue, headache, nausea, and pruritus. Critically, no treatment discontinuations occurred in either group, a finding that speaks both to the tolerability of the regimen and to the adherence of the patients, who completed the full twelve weeks despite the challenges of accessing care in a resource-limited health system.

Perhaps equally notable was what did not predict treatment failure. The researchers found that age, sex, and diabetes mellitus were not associated with SVR12 outcomes, suggesting that the regimen’s efficacy was robust across the demographic and metabolic spectrum represented in the cohort. This is consistent with the broader literature on direct-acting antivirals, which have repeatedly demonstrated that host factors matter far less than they did in the interferon era. When cure rates approach the mid-nineties, there is simply little room for baseline characteristics to exert a measurable effect. The near-identical results in previously treated patients are particularly significant, because prior interferon failure has historically been one of the strongest predictors of poor response to subsequent therapy.

The Yemeni context gives these findings an urgency that extends beyond the clinic. Yemen’s health infrastructure has been severely strained by conflict, and access to specialized diagnostics and medications remains limited for much of the population. Chronic hepatitis C, if left untreated, progresses over years to cirrhosis and, in a subset of patients, to hepatocellular carcinoma, the most common primary liver cancer. Every patient cured is a patient removed from that trajectory, and every cured patient also reduces ongoing transmission in the community. The World Health Organization has set ambitious global targets for hepatitis C elimination, and achieving them will depend heavily on demonstrating that direct-acting antiviral regimens work as well in real-world, resource-constrained settings as they do in the controlled environments of pharmaceutical company trials. This study provides exactly that kind of evidence for Yemen.

The retrospective design of the study does impose limitations that the authors and readers must keep in mind. Retrospective cohorts rely on existing medical records rather than prospective randomization, which can introduce selection bias and incomplete data capture. The sample size of one hundred, while adequate for detecting the headline result, is modest, and the absence of genotype-specific subgroup analyses in the reported findings leaves open questions about whether certain viral strains circulating in Yemen respond differently to ledipasvir. The twelve-week follow-up window, while the accepted standard for SVR12, cannot capture very late relapses, although these are rare with direct-acting antiviral therapy. Nonetheless, the consistency of the results with international trial data strengthens confidence that the findings are generalizable.

The study also carries practical implications for treatment policy in Yemen and comparable settings. Because prior treatment status did not affect outcomes, clinicians in resource-limited environments may not need to reserve direct-acting antivirals exclusively for treatment-naïve patients or to construct complex algorithms based on prior interferon exposure. A single, uniform twelve-week regimen of ledipasvir/sofosbuvir plus ribavirin appears capable of curing the vast majority of chronic hepatitis C patients regardless of history. Simplification of this kind is a genuine asset where specialist expertise is scarce and where every additional diagnostic test or treatment modification adds cost and delay. The authors conclude that the regimen is safe, well tolerated, and highly effective, and that these findings support the adoption of direct-acting antivirals as the standard of care in resource-limited settings.

As the global campaign against hepatitis C moves from trial evidence to elimination targets, studies like this one fill a crucial gap. They demonstrate that the scientific advances of the past decade are not confined to wealthy health systems but can deliver near-universal cure rates in one of the world’s most challenging environments. For the ninety-five of one hundred Yemeni patients in this cohort who cleared their infection, the result is concrete: a virus that once promised cirrhosis or cancer has been eradicated from their blood with twelve weeks of oral therapy. For the clinicians and public health officials working toward hepatitis C elimination in the Eastern Mediterranean, the message is equally clear—modern antiviral therapy works, and it works for everyone.

Subject of Research: Sustained virologic response to ledipasvir/sofosbuvir plus ribavirin therapy in treatment-naïve and previously treated chronic hepatitis C patients in Yemen

Article Title: Comparison of sustained virologic responses to ledipasvir/sofosbuvir plus ribavirin therapy between previously treated and naïve patients with chronic hepatitis c in yemen: a retrospective comparative cohort study

Article References: Al-Faqih, M. H., Bahaj, S. S., Othman, A. M., Al-Amrani, M. A., & Assayaghi, R. M. (2026). Comparison of sustained virologic responses to ledipasvir/sofosbuvir plus ribavirin therapy between previously treated and naïve patients with chronic hepatitis c in yemen: a retrospective comparative cohort study. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14550-6

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14550-6

Keywords: hepatitis C, hepatitis C virus, direct-acting antivirals, ledipasvir, sofosbuvir, ribavirin, sustained virologic response, Yemen, pegylated interferon, anemia, BMC Infectious Diseases, resource-limited settings